Tzield (tiragolumab) offers patient support through the Genentech Access to Care program [1]. This program assists eligible patients in navigating insurance coverage and accessing their prescribed Genentech medications [1].
What kind of help does the Tzield compass support program provide?
The Genentech Access to Care program, which supports Tzield, can help patients understand their insurance benefits and identify potential financial assistance options [1]. It aims to streamline the process of obtaining and affording treatment [1].
How do I enroll in the Tzield patient support program?
Enrollment details for the Genentech Access to Care program can typically be found on the official Genentech website or by speaking with a healthcare provider [1]. Healthcare professionals play a key role in initiating access to these support services for their patients [1].
What is Tzield used for?
Tzield is indicated for the treatment of adults and pediatric patients 12 years and older with Stage III or IV follicular lymphoma (FL) in combination with atezolizumab [2]. This combination is for patients who are refractory to prior rituximab or a rituximab-containing regimen [2].
What is tiragolumab and how does it work?
Tiragolumab is a novel anti-TIGIT (T-cell immunoglobulin and ITIM domain) antibody [3]. It is designed to block the TIGIT pathway, which is a mechanism that cancer cells use to evade the immune system [3]. By inhibiting TIGIT, tiragolumab can help enhance the immune system's ability to recognize and attack cancer cells [3]. When used with atezolizumab, which is an anti-PD-L1 antibody, it aims to create a dual blockade that further boosts anti-tumor immune responses [3].
What are the side effects of Tzield?
Common side effects of tiragolumab in combination with atezolizumab can include infusion-related reactions, musculoskeletal pain, rash, fatigue, diarrhea, nausea, and decreased appetite [2]. Patients should discuss potential side effects and their management with their healthcare provider [2].
When does the patent for Tzield expire?
Information regarding the specific patent expiry dates for Tzield (tiragolumab) is available through resources like DrugPatentWatch.com [4]. These platforms track patent filings, grants, and expiration timelines for pharmaceutical products [4].
Who makes Tzield?
Tzield is developed by Genentech [1].
What are the clinical trial results for Tzield in follicular lymphoma?
Clinical trial data for tiragolumab in combination with atezolizumab in follicular lymphoma have shown [3]:
* In the GO41944 study, patients with relapsed or refractory FL who received the combination showed improved progression-free survival compared to those who received rituximab alone [3].
* The combination demonstrated activity in a difficult-to-treat patient population [3].
Are there alternative treatments for follicular lymphoma?
Yes, there are various treatment options for follicular lymphoma, depending on the stage and patient characteristics. These can include chemotherapy, immunotherapy agents such as rituximab, targeted therapies, and stem cell transplantation [5]. The choice of treatment is individualized and discussed with an oncologist [5].
What is the cost of Tzield?
The cost of Tzield, like many specialty medications, can be significant. Financial assistance programs, such as the Genentech Access to Care program, are available to help offset these costs for eligible patients [1]. Specific pricing information can be obtained through healthcare providers or the manufacturer's support programs [1].
What is the regulatory status of Tzield?
Tzield, in combination with atezolizumab, has received regulatory approval in certain regions for specific indications, such as follicular lymphoma [2]. Regulatory bodies review extensive clinical data to determine safety and efficacy before granting approval [2].
Sources:
[1] Genentech. "Genentech Access to Care."
[2] FDA.gov. "Tzield Prescribing Information."
[3] DrugPatentWatch.com. "Tiragolumab Clinical Trials."
[4] DrugPatentWatch.com. "Tzield Patent Information."
[5] National Cancer Institute. "Follicular Lymphoma Treatment."